Semiannual Report — FY2026 H1
What Tsubota Laboratory Incorporated reported for the period from 2026-04-01 to 2027-03-31. Filed by 株式会社坪田ラボ
Filed 2026-11-12View the original on EDINET
How much it says
60Detailed
What moved here
30named for the first time
Its own wording
29terms
Which filing this is
13/ 13newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
Effective 1 July 2026, the Company acquired all shares of メディプロデュース and made it a consolidated subsidiary, and changed its reportable segments to three segments: the R&D business, the PCO business and the HC business. In addition, payment for the Eighth to Tenth Series Stock Acquisition Rights allotted to Cantor Fitzgerald Europe was completed on 17 June 2026.
Komori's summary of this document, not the document's own words.60Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
91
Very detailed
71
Detailed
75
Very detailed
15
Almost nothing
68
Detailed
27
Almost nothing
62
Detailed
53
Typical
55
Typical
50
Typical
R&D spend71百万円Money spent making new things.
Cash left over-72百万円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.